All Outputs (10)

Cancer patients’ experiences of the diagnosis and treatment of incidental pulmonary embolism (a qualitative study) (2022)
Journal Article
Benelhaj, N. E., Hutchinson, A., Maraveyas, A., & Johnson, M. (2022). Cancer patients’ experiences of the diagnosis and treatment of incidental pulmonary embolism (a qualitative study). PLoS ONE, 17(10), Article e0276754. https://doi.org/10.1371/journal.pone.0276754

Background: The diagnosis of symptomatic cancer-associated thrombosis often causes distress and alarm for patients, especially for those unaware of the risk, or the signs and symptoms to look out for. There are few data about cancer patients’ experie... Read More about Cancer patients’ experiences of the diagnosis and treatment of incidental pulmonary embolism (a qualitative study).

Tumour-Associated Tissue Factor (TF)-mRNA Is A Precursor for Rapid TF-Microvesicle Release and A Potential Predictive Marker for the Risk of Pulmonary Embolism (PE) in Gastrointestinal Cancer Patients (2022)
Journal Article
Ettelaie, C., Benelhaj, N., Featherby, S., Haque, F., Johnson, M., Cooke, J., & Maraveyas, A. (2022). Tumour-Associated Tissue Factor (TF)-mRNA Is A Precursor for Rapid TF-Microvesicle Release and A Potential Predictive Marker for the Risk of Pulmonary Embolism (PE) in Gastrointestinal Cancer Patients. Journal of Biotechnology and Biomedicine, 5(2), 78-93. https://doi.org/10.26502/jbb.2642-280050

Predicting which cancer patients are at risk of thrombosis remains a key challenge to effective thromboprophylaxis. This study was based on the hypothesis that the rapid release of TF-containing MV occurs in cancer cells that possess high levels of T... Read More about Tumour-Associated Tissue Factor (TF)-mRNA Is A Precursor for Rapid TF-Microvesicle Release and A Potential Predictive Marker for the Risk of Pulmonary Embolism (PE) in Gastrointestinal Cancer Patients.

Alteration in endothelial permeability occurs in response to the activation of PAR2 by factor Xa but not directly by the TF-factor VIIa complex (2019)
Journal Article
Benelhaj, N. E., Maraveyas, A., Featherby, S., Collier, M. E., Johnson, M. J., & Ettelaie, C. (2019). Alteration in endothelial permeability occurs in response to the activation of PAR2 by factor Xa but not directly by the TF-factor VIIa complex. Thrombosis Research, 175, 13-20. https://doi.org/10.1016/j.thromres.2019.01.009

Alterations in the endothelial permeability occur in response to the activation of coagulation mechanisms in order to control clot formation. The activation of the protease activated receptors (PAR) can induce signals that regulate such cellular resp... Read More about Alteration in endothelial permeability occurs in response to the activation of PAR2 by factor Xa but not directly by the TF-factor VIIa complex.

Oral anticoagulation is preferable to injected, but only if it is safe and effective: An interview study of patient and carer experience of oral and injected anticoagulant therapy for cancer-associated thrombosis in the select-d trial (2018)
Journal Article
Hutchinson, A., Rees, S., Young, A., Maraveyas, A., Date, K., & Johnson, M. J. (2019). Oral anticoagulation is preferable to injected, but only if it is safe and effective: An interview study of patient and carer experience of oral and injected anticoagulant therapy for cancer-associated thrombosis in the select-d trial. Palliative medicine, 33(5), 510-517. https://doi.org/10.1177/0269216318815377

Background: Cancer patients have a four- to fivefold greater risk of thrombosis than the general population. Recommended treatment for cancer-associated thrombosis is 3–6 months of low-molecular-weight heparin. The ‘select-d’ trial is an open-label,... Read More about Oral anticoagulation is preferable to injected, but only if it is safe and effective: An interview study of patient and carer experience of oral and injected anticoagulant therapy for cancer-associated thrombosis in the select-d trial.

CAMERA - complete assessment of elderly patients with cancer: A non-randomised feasibility study (2018)
Journal Article
Jackson, G., Gabe, R., Johnson, M., Date, K., Harman, D., Maraveyas, A., …Lind, M. J. (2019). CAMERA - complete assessment of elderly patients with cancer: A non-randomised feasibility study. Journal of Geriatric Oncology, 10(1), 175-177. https://doi.org/10.1016/j.jgo.2018.07.005

One of the primary risk factors in the development of cancer is older age. The demographic shift to an ageing population has given rise to an increased number of older patients with cancer. The extreme heterogeneity within this population renders app... Read More about CAMERA - complete assessment of elderly patients with cancer: A non-randomised feasibility study.

Cancer patients’ experiences of living with venous thromboembolism: A systematic review and qualitative thematic synthesis (2018)
Journal Article
Benelhaj, N. B., Hutchinson, A., Maraveyas, A. M., Seymour, J. D., Ilyas, M. W., & Johnson, M. J. (2018). Cancer patients’ experiences of living with venous thromboembolism: A systematic review and qualitative thematic synthesis. Palliative medicine, 32(5), 1010-1020. https://doi.org/10.1177/0269216318757133

Background: Cancer-Associated thrombosis is common. Recommended treatment is daily injected low-molecular-weight heparin for 6months. Most studies focus on prophylaxis and treatment; few have explored patients’ experience. Aims To identify and sy... Read More about Cancer patients’ experiences of living with venous thromboembolism: A systematic review and qualitative thematic synthesis.

The ethical decisions UK doctors make regarding advanced cancer patients at the end of life - the perceived (in) appropriateness of anticoagulation for venous thromboembolism: A qualitative study (2012)
Journal Article
Sheard, L., Prout, H., Dowding, D., Noble, S., Watt, I., Maraveyas, A., & Johnson, M. (2012). The ethical decisions UK doctors make regarding advanced cancer patients at the end of life - the perceived (in) appropriateness of anticoagulation for venous thromboembolism: A qualitative study. BMC medical ethics, 13(22), Article ARTN 22. https://doi.org/10.1186/1472-6939-13-22

Background: Cancer patients are at risk of developing blood clots in their veins - venous thromboembolism (VTE) - which often takes the form of a pulmonary embolism or deep vein thrombosis. The risk increases with advanced disease. Evidence based tre... Read More about The ethical decisions UK doctors make regarding advanced cancer patients at the end of life - the perceived (in) appropriateness of anticoagulation for venous thromboembolism: A qualitative study.

Diagnosis and management of people with venous thromboembolism and advanced cancer: how do doctors decide? a qualitative study (2012)
Journal Article
Johnson, M. J., Sheard, L., Maraveyas, A., Noble, S., Prout, H., Watt, I., & Dowding, D. (2012). Diagnosis and management of people with venous thromboembolism and advanced cancer: how do doctors decide? a qualitative study. BMC Medical Informatics and Decision Making, 12(75), https://doi.org/10.1186/1472-6947-12-75

Background: The treatment of cancer associated thrombosis (CAT) is well established, with level 1A evidence to support the recommendation of a low molecular weight heparin (LMWH) by daily injection for 3-6 months. However, registry data suggest compl... Read More about Diagnosis and management of people with venous thromboembolism and advanced cancer: how do doctors decide? a qualitative study.

Does clinical method mask significant VTE-related mortality and morbidity in malignant disease? Mini review. (2009)
Journal Article
Johnson, M., & Maraveyas, A. (2009). Does clinical method mask significant VTE-related mortality and morbidity in malignant disease? Mini review. The British Journal of Cancer, 100(12), 1837 - 1841. https://doi.org/10.1038/sj.bjc.6605091

After more than 150 years of a recognised link between cancer and vascular thromboembolic events (VTE), and despite a greatly improved understanding of its pathophysiology, epidemiology and treatment, the management of patients with cancer and VTE is... Read More about Does clinical method mask significant VTE-related mortality and morbidity in malignant disease? Mini review..

Does clinical method mask significant VTE-related mortality and morbidity in malignant disease? (2009)
Journal Article
Johnson, M., & Maraveyas, A. (2009). Does clinical method mask significant VTE-related mortality and morbidity in malignant disease?. The British Journal of Cancer, 100(12), 1837-1841. https://doi.org/10.1038/sj.bjc.6605091

After more than 150 years of a recognised link between cancer and vascular thromboembolic events (VTE), and despite a greatly improved understanding of its pathophysiology, epidemiology and treatment, the management of patients with cancer and VTE is... Read More about Does clinical method mask significant VTE-related mortality and morbidity in malignant disease?.